|
a. This is a case of incomplete dominance. |
||
|
b. This is a case of dominant inheritance. |
||
|
c. This is a case of recessive inheritance. |
||
|
d. This is a case of Mendelian inheritance. |
|
a. The husband is right; he cannot be the father. The father of the child must have AB or B blood type. |
||
|
b. The husband is right; he cannot be the father. The father of the child must have O blood type. |
||
|
c. The husband is wrong. He can be the father, if his genotype is AO. |
||
|
d. The husband is wrong. He can be the father, if his genotype is AA. |
|
a. 1 in 16 |
||
|
b. 2 in 16 |
||
|
c. 3 in 16 |
||
|
d. 9 in 16 |
|
a. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be blue-eyed and have Bb or BB genotype. |
||
|
b. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be blue-eyed and have Bb or BB genotype. |
||
|
c. No, because Jane has BB genotype and Joe has Bb genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be brown-eyed and have Bb or BB genotype. |
||
|
d. No, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be brown-eyed and have Bb or BB genotype. |
|
a. Conventional PCR |
||
|
b. RT-PCR |
||
|
c. Real-time RT-PCR |
||
|
d. Subtractive hybridization |
|
a. 4 |
||
|
b. 8 |
||
|
c. 16 |
||
|
d. 32 |
|
a. Ribozymes |
||
|
b. RNAi |
||
|
c. MicroRNA |
||
|
d. Riboswithes |
|
a. In the cgfp gene, the codon usage is C. reinhardtii-conform. |
||
|
b. The cgfp gene is expressing a different GFP protein sequence. |
||
|
c. The cgfp gene is expressing a GFP protein with different color. |
||
|
d. In the cgfp gene, there are fewer introns. |
|
a. Conventional PCR |
||
|
b. RT-PCR |
||
|
c. Real-time RT-PCR |
||
|
d. Subtractive hybridization. |
|
a. Radioactive |
||
|
b. Fluorescent |
||
|
c. Silver-enhanced gold |
||
|
d. Photoenhanced |
|
a. Junk DNA |
||
|
b. Pseudogene |
||
|
c. Long repeat |
||
|
d. Non-coding region |
|
a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. |
||
|
b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. |
||
|
c. Scaffolds are sequenced and contigs are built from scaffolds. |
||
|
d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
|
a. Divergence, common ancestor |
||
|
b. Distance, common ancestor |
||
|
c. Divergence, distance |
||
|
d. Distance, adaptation |
|
a. Higher |
||
|
b. Lower |
||
|
c. Unchanged |
||
|
d. Negligible |
|
a. Genes which are not expressed differentially in tumor and normal cells. |
||
|
b. Genes which are overexpressed in normal cells. |
||
|
c. Genes which are overexpressed in tumor cells. |
||
|
d. Promoter sequences which are particularly active in tumor cells. |
|
a. RNA—protein interaction prediction. |
||
|
b. Gene prediction. |
||
|
c. Open reading frame prediction. |
||
|
d. Nucleic acid sequence translation to protein sequence. |
|
a. Euchromatin |
||
|
b. Heterochromatin |
||
|
c. Telomere |
||
|
d. Centromere |
|
a. Short known DNA sequences can be synthesized chemically directly on chip. |
||
|
b. All genes of an organism can be bound in microarrays, and these arrays can be used in differential gene expression studies. |
||
|
c. Microarrays made from the genome of an organism are typically probed with a whole genomic DNA probe made from the same organism. |
||
|
d. Fluorescent probes can be used to identify genes on microarrays. |
|
a. 10 and 6 |
||
|
b. 11 and 6 |
||
|
c. 14 and 6 |
||
|
d. 11 and 10 |
|
a. DNA extraction, restriction enzymes, and Southern blot |
||
|
b. DNA extraction, PCR, and Southern blot |
||
|
c. DNA extraction, restriction enzymes, and Western blot |
||
|
d. DNA extraction, PCR, and Western blot |
|
a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. |
||
|
b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. |
||
|
c. Scaffolds are sequenced and contigs are built from scaffolds. |
||
|
d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
|
a. A single nucleotide change. |
||
|
b. A single codon change. |
||
|
c. A single amino acid change. |
||
|
d. A small genetic change. |
|
a. The ratio of poly-Q and poly-A |
||
|
b. The total length of poly-Q and poly-A |
||
|
c. Only the length of poly-Q |
||
|
d. Only the length of poly-A |
|
a. Proteomics |
||
|
b. Metagenomics |
||
|
c. Metabolomics |
||
|
d. Proteomics |
|
a. ABC |
||
|
b. ACB |
||
|
c. CAB |
||
|
d. CBA |
|
a. Metagenomics |
||
|
b. Envirogenomics |
||
|
c. Nature genomics |
||
|
d. Microbiomics |
|
a. Genetic map. |
||
|
b. Physical map |
||
|
c. Open reading frame |
||
|
d. Gene sequence |
|
a. Model organisms have genes similar to human genes. |
||
|
b. Model organisms are mainly used to highlight the differences between animals and humans. |
||
|
c. Model organisms can attract animal-loving students to genomics. |
||
|
d. A focus on the differences contributes to our understanding of genetic inheritance. |
|
a. Proteomics |
||
|
b. Metagenomics |
||
|
c. Metabolomics |
||
|
d. Proteomics |
|
a. Crossing over of the sister chromatids during meiosis I. |
||
|
b. Crossing over of the non-sister chromatids during meiosis I. |
||
|
c. Crossing over of the sister chromatids during meiosis II. |
||
|
d. Crossing over of the non-sister chromatids during meiosis II. |
|
a. Design gene therapy |
||
|
b. Clone animals |
||
|
c. Combine functional units of different proteins |
||
|
d. Generate novel cell types |
|
a. Cell differentiation |
||
|
b. Meiosis |
||
|
c. The locus of gene insertion |
||
|
d. Codon preference |
|
a. Transposable elements |
||
|
b. Proteases |
||
|
c. Epigenetic changes |
||
|
d. DNA methylation |
|
a. Lysosomes |
||
|
b. Extracellular space |
||
|
c. Nucleus |
||
|
d. Golgi |
|
a. Affinity chromatography and immunoprecipitation |
||
|
b. Exclusion chromatography and immunoprecipitation |
||
|
c. Western blot and exclusion chromatography |
||
|
d. Western blot and Northern blot |
|
a. Higher temperatures utilizing the increased Brownian motion |
||
|
b. The presence of complementing surfaces |
||
|
c. Processing enzymes which seal the protein in the right conformation with chemical bonds |
||
|
d. Chaperones that prevent premature aggregation of hydrophobic regions |
|
a. Dideoxy sequencing |
||
|
b. Edman degradation |
||
|
c. MALDI |
||
|
d. MS-MS |
|
a. Dideoxy sequencing |
||
|
b. Edman degradation |
||
|
c. MALDI |
||
|
d. MS-MS |
|
a. Can be modified posttranslationally |
||
|
b. Cannot be modified posttranslationally |
||
|
c. Are spontaneously secreted |
||
|
d. Are synthesized on ribosomes |
|
a. A separate surface from the DNA |
||
|
b. The surface as the DNA |
||
|
c. An antibody capture array |
||
|
d. A functional array |
|
a. Greatly |
||
|
b. Hardly |
||
|
c. Never |
||
|
d. Temporarily |
|
a. Simultaneously, enhancers |
||
|
b. Simultaneously, operons |
||
|
c. Consecutively, enhancers |
||
|
d. Consecutively, operons |
|
a. Eastern blot |
||
|
b. Northern blot |
||
|
c. Southern blot |
||
|
d. Western blot |
|
a. Size |
||
|
b. Shape |
||
|
c. Electric charge |
||
|
d. Polarity |
|
a. Burst |
||
|
b. Stay intact |
||
|
c. Shrink |
||
|
d. Divide |
|
a. Genomes |
||
|
b. Viruses |
||
|
c. Plasmids |
||
|
d. Vectors |
|
a. Reporter genes |
||
|
b. Selection genes |
||
|
c. Detection genes |
||
|
d. Promoters |
|
a. Knock-out |
||
|
b. Random insertion |
||
|
c. Mutated |
||
|
d. Inverted |
|
a. Providing extracellular matrix for |
||
|
b. Adding Ti plasmid to the growth medium of |
||
|
c. Inducing de-differentiation of |
||
|
d. Inducing viral gene transfer of |
|
a. Zinc |
||
|
b. Iron |
||
|
c. Selenium |
||
|
d. flavin |
|
a. Somatic |
||
|
b. Multipotent stem |
||
|
c. Totipotent stem |
||
|
d. Germ |
|
a. Only recessive homozygous |
||
|
b. Only homozygous traits |
||
|
c. Only dominant genes |
||
|
d. A desired combination of recessive and dominant genes |
|
a. Hair shaft |
||
|
b. Saliva |
||
|
c. Blood |
||
|
d. Milk |
|
a. Genetic mosaics |
||
|
b. Hybridomas |
||
|
c. Genetic mixtures |
||
|
d. Hybrids |
|
a. Somatic cell nuclear transfer |
||
|
b. Germ line nuclear transfer |
||
|
c. In vitro fertilization |
||
|
d. Recombineering |
|
a. Her shorter than average |
||
|
b. Her longer than average |
||
|
c. The absence of the |
||
|
d. The branching |
|
a. Forward genetic |
||
|
b. Reverse genetic |
||
|
c. Transgenic |
||
|
d. Mutagenic |
|
a. Substantial homologous |
||
|
b. Minimal homologous |
||
|
c. Substantial heterologous |
||
|
d. Minimal heterologous |
|
a. Site specific insertion; neutralization of position effects |
||
|
b. Neutralization of position effects; site specific insertion |
||
|
c. P element insertion; recombinases and integrases |
||
|
d. Recombinases and integrases; P element insertion. |
|
a. offer protection against |
||
|
b. enhance |
||
|
c. attenuate insect bites delivering |
||
|
d. intensify |
|
a. Preimplantation genetic diagnosis |
||
|
b. Postimplantation genetic diagnosis |
||
|
c. Prefertilization genetic diagnosis |
||
|
d. Genetic counseling |
|
a. Blue fluorescent protein |
||
|
b. Green fluorescent protein |
||
|
c. Red fluorescent protein |
||
|
d. Yellow fluorescent protein |
|
a. Insertion position |
||
|
b. Activity |
||
|
c. High copy number |
||
|
d. Inactivity |
|
a. DNA methylation |
||
|
b. Chromosomal rearrangement |
||
|
c. Missense mutation |
||
|
d. Chromosomal inversion |
|
a. 16 % |
||
|
b. 30% |
||
|
c. 40% |
||
|
d. 90% |
|
a. Stem cells; virus transformed cells |
||
|
b. Blood cells; virus transformed cells |
||
|
c. Stem cells; mutated cells |
||
|
d. Blood cells; mutated cells |
|
a. Zinc-finger nuclease |
||
|
b. Protease |
||
|
c. Antibody |
||
|
d. Lipase |
|
a. Every; every |
||
|
b. Every; a tumor |
||
|
c. A tumor, a tumor |
||
|
d. A tumor, every |
|
a. 0% |
||
|
b. 25% |
||
|
c. 50% |
||
|
d. 75% |
|
a. Point; malaria parasite |
||
|
b. Nonsense; malaria parasite |
||
|
c. Point; papillomavirus |
||
|
d. Nonsense; papillomavirus |
|
a. Gene gun, gold |
||
|
b. Gene gun, iron |
||
|
c. Particle gun, gold |
||
|
d. Particle gun, iron |
|
a. Turner |
||
|
b. Klinefelter |
||
|
c. Down |
||
|
d. Edwards |
|
a. Not wear off as we age; can |
||
|
b. Wear off as we age; can |
||
|
c. Not wear off as we age; cannot |
||
|
d. Wear off as we age; cannot |
|
a. Noncoding chromosomal regions |
||
|
b. Coding chromosomal regions |
||
|
c. One chromosome |
||
|
d. Sex chromosomes |
|
a. Simplicity of |
||
|
b. Instantaneous result of |
||
|
c. Statistical strength linked to |
||
|
d. Variety of available protocols for |
|
a. If a Y-typing is performed and shows that Mr. X’s Y chromosome is identical to the Y chromosome of Ms. Y’s son, then Mr. X must be the father. |
||
|
b. If a Y-typing is performed and shows that Mr. X’s Y chromosome is identical to the Y chromosome of Ms. Y’s son, then Mr. X or another man of his paternal line must be the father. |
||
|
c. If forensic DNA-typing is performed utilizing the standard 13 STR regions and shows that Mr. Y’s son has one-one allele of Mr. X’s each analyzed STR allele pair, then Mr. X must be the father. |
||
|
d. DNA fingerprinting cannot prove that Mr. X is the father of Ms. Y’s son. But if they are father and son, their friction ridge patterns will be identical on all of their fingers. |
|
a. Fermentation |
||
|
b. Extraction |
||
|
c. Bioaccumulation |
||
|
d. Bioamplification |
|
a. Single-species; multi-species |
||
|
b. Multi-species; single-species |
||
|
c. Single-layer; multi-layer |
||
|
d. Multi-layer; single-layer |
|
a. Biochemical reactions |
||
|
b. Microbes |
||
|
c. Plants |
||
|
d. Animals |
|
a. As carbonate-based concrete |
||
|
b. As Roman-style |
||
|
c. As concrete |
||
|
d. Underground |
|
a. Fermentation |
||
|
b. Extraction |
||
|
c. Bioaccumulation |
||
|
d. Bioamplification |
|
a. Simple; longer |
||
|
b. Technologically challenging; shorter |
||
|
c. Simple; shorter |
||
|
d. Technologically challenging; longer |
|
a. Bacteria |
||
|
b. Plants |
||
|
c. Birds |
||
|
d. Fishes |
|
a. Simple; longer |
||
|
b. Technologically challenging; shorter |
||
|
c. Simple; shorter |
||
|
d. Technologically challenging; longer |
|
a. Soluble in fat. |
||
|
b. Hydrophilic. |
||
|
c. Stable. |
||
|
d. Biologically active. |
|
a. Bacteria |
||
|
b. Plant |
||
|
c. Bird |
||
|
d. Fish |
|
a. Four |
||
|
b. Five |
||
|
c. Six |
||
|
d. Seven |
|
a. Chemostat |
||
|
b. Traditional liquid culture |
||
|
c. Semisolid culture |
||
|
d. Subculture |
|
a. Bioleaching |
||
|
b. Bioremediation |
||
|
c. In situ |
||
|
d. Biofilm |
|
a. Hydrogenases |
||
|
b. Hydrogen ion pumps |
||
|
c. Electron transport chain |
||
|
d. ATP |
|
a. isobutanol |
||
|
b. glucose |
||
|
c. penicillin |
||
|
d. hydrogen |
|
a. Just a fancy name for a multivitamin complex |
||
|
b. An antigen engineered into a plant we eat |
||
|
c. An attenuated oral vaccine, like the Sabin drops |
||
|
d. An antibody engineered into the plant we eat |
|
a. Saccharopolyspora erythraea |
||
|
b. Saccharomyces cerevisiae |
||
|
c. Streptomyces parvullus |
||
|
d. Clostridium cellulolyticum |
|
a. Lead to gene doping |
||
|
b. Initiate intensive wellness activities |
||
|
c. Can be easily accepted in sports |
||
|
d. Might to be legalized soon |
|
a. Genetic counseling |
||
|
b. Pharmacogenomics |
||
|
c. Pharmacokinetics |
||
|
d. Pharmacology |
|
a. Protect against the body’s immune response |
||
|
b. Bring another alternative to the market |
||
|
c. Follow these particles with body scanning |
||
|
d. Determine how fat particles leaves the body |
|
a. to build organs that are not rejected |
||
|
b. for future applications |
||
|
c. for donation |
||
|
d. in cloning |
|
a. Embryonic stem cells |
||
|
b. Somatic stem cells |
||
|
c. Adult stem cells |
||
|
d. Multipotent stem cells |
|
a. Mycoplasma Laboratorium |
||
|
b. Agrobacterium tumefaciens |
||
|
c. Escherichia coli |
||
|
d. Saccharomyces cerevisiae |
|
a. Radioimmunotherapy |
||
|
b. Radiotoxins |
||
|
c. Radiation therapy |
||
|
d. Chemotherapy |